Aktienanalyse zu Rigel Pharmaceuticals Inc (RIGL)RIGLRigel Pharmaceuticals Inc

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Rigel Pharmaceuticals Inc (RIGL) appears to be a good buy right now, given its current price of $45.97, a forward P/E ratio of 9.29, and a gross margin of 89.17%. The company has shown robust revenue growth, with Q2 2026 revenues of $78.7 million and a raised total revenue guidance for 2026 to between $285 million and $295 million. However, the main risk is the RSI at 33.31, indicating potential oversold conditions which could lead to further price volatility.

3 analysts cover RIGL: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 52.00.